Heron Therapeutics (NASDAQ:HRTX) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.15, Briefing.com reports. The business had revenue of $42.62 million during the quarter, compared to the consensus estimate of $34.02 million. Heron Therapeutics had a negative return on equity of 58.49% and a negative net margin of 140.55%. Heron Therapeutics’s quarterly revenue was up 115.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.49) earnings per share.
Heron Therapeutics stock traded up $0.74 during trading hours on Friday, reaching $21.58. 1,179,053 shares of the company’s stock were exchanged, compared to its average volume of 992,970. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. The firm’s 50 day simple moving average is $19.48 and its 200 day simple moving average is $18.58. Heron Therapeutics has a twelve month low of $15.68 and a twelve month high of $29.49. The firm has a market capitalization of $1.66 billion, a PE ratio of -8.85 and a beta of 1.44.
In other Heron Therapeutics news, CEO Barry D. Quart purchased 4,571 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was purchased at an average cost of $17.50 per share, for a total transaction of $79,992.50. Following the acquisition, the chief executive officer now owns 90,081 shares in the company, valued at approximately $1,576,417.50. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John Poyhonen purchased 11,105 shares of the firm’s stock in a transaction on Monday, September 30th. The shares were acquired at an average price of $22.62 per share, with a total value of $251,195.10. Over the last quarter, insiders have acquired 306,533 shares of company stock valued at $5,421,185. Company insiders own 12.56% of the company’s stock.
A number of analysts recently weighed in on HRTX shares. Northland Securities restated a “buy” rating and issued a $47.00 price objective on shares of Heron Therapeutics in a report on Wednesday. JMP Securities decreased their price objective on Heron Therapeutics from $38.00 to $32.00 and set a “market outperform” rating for the company in a report on Thursday, October 3rd. Stifel Nicolaus restated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a report on Monday, August 5th. Svb Leerink restated an “outperform” rating on shares of Heron Therapeutics in a report on Tuesday. Finally, Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $49.43.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.